Cipla Health takes a humorous spin on real life stories with Astaberry's campaign 'Get the Rich Look'
Rooted in nature and designed for the women of Bharat, the campaign celebrates radiant, healthy skin that shines naturally, empowering women to step forward with confidence in every walk of life. Drawing inspiration from real stories shared by our consumers, the film highlights how Astaberry's simple, effective skincare solutions can help women achieve a naturally radiant 'Rich Look'.
The film charmingly highlights relatable scenarios with a light-hearted and authentic tone where a subtle beauty upgrade transforms how the world perceives a woman, whether it's meeting someone new, preparing for an important occasion, or stepping into a professional setting.
Commenting on the campaign, Mr. Shivam Puri, MD & CEO, Cipla Health Ltd. said, "At Cipla Health, we are committed to bringing solutions that are effective, accessible, and seamlessly fit into the lives of our consumers. This campaign is deeply rooted in real consumer insights and offers a refreshing take on the quiet confidence that naturally radiant skin brings. Astaberry has always stood for nature-powered skincare that is reliable, affordable, and designed for all skin types. As the beauty and personal care market expands rapidly, especially beyond metros, this film reinforces our commitment to offering trusted solutions that meet the evolving aspirations of women across India." Astaberry*, with a legacy of over 16 years, offers a comprehensive skincare portfolio across more than 10 categories and 250 products. From hair removal creams and face washes to serums, sun protection, and facial kits, each product is infused with nature-based ingredients like papaya, red grapes, strawberry, licorice, mulberry, and rose. The formulations are thoughtfully crafted for all skin types, offering affordable and effective skincare that aligns with the needs of today's aspirational consumers.
*The second-largest player in the hair removal cream category and the fastest-growing brand among the top five.
Agency Credits : Agency: The Womb Founding Partner: Kawal Shoor and Navin Talreja COO: Dhaval Jadwani CCO: Suyash Khabya Creative: Sohil Wadhwania, Shiv Parashar, Komal Sharma, Anshu Gupta Planner: Gaurav Joshi, Jasmin Tripathy Account Management: Rajat Pandey, Deepshikha Dutta Production House: Creature Film Company Director: Joyeeta Patpatia Producer : Ramel George Watch the films here Facial kit : https://youtu.be/LsT-oP79Qvs HRC : https://youtu.be/EuB9Jg7GI1o About Cipla Health Limited: Cipla Health Limited, the fast-moving wellness goods (FMWG) arm of Cipla, was incorporated in 2015 with a vision to spearhead the wellness wave in India. Cipla Health has delivered rapid growth and today plays across a diverse portfolio of 20 brands with most key brands being No. 1 or No. 2 in their respective categories. The portfolio includes products in Pain Care (Omnigel), Smoking Cessation (Nicotex), Oral Rehydration Solutions (Prolyte), Medicated Ointments (Cipladine), Cough & Cold (Cofsils and Naselin), Multi Vitamins (Maxirich), Weight Gain (Endura Mass) and Personal Care (Rivela Dermascience, Cetafresh, Tugain Essentials, Astaberry).
Logo: https://mma.prnewswire.com/media/2658055/5252537/Cipla_Health_Logo.jpg (Disclaimer: The above press release comes to you under an arrangement with PRNewswire and PTI takes no editorial responsibility for the same.).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
12 hours ago
- Time of India
From ouch to opportunity: India chases instant relief as pain market swells to Rs 16,000 crore; 5 brands pop up every week
India's pain relieving market is soaring, as more and more people are rushing to use over-the-counter (OTC) pills, sprays and creams to soothe everyday aches and pains. According to Nielsen data cited by industry executives, in the past five years, the segment has grown by more than a billion dollars, becoming the largest category within the non-prescription space. Since the onset of the pandemic, around five new pain relief brands have been launched each week on average, as per an ET report. In 2020, there were 1,552 brands catering to pain relief, including household names such as Volini, Omnigel, Dolo and Saridon. That figure has now soared to 2,771. Consumers are prioritising quick relief, said Shivam Puri, managing director at Cipla Health, 'Rise of urbanisation and increase in chronic illnesses have led to the need for faster, more convenient formats that are accessible across platforms,' Puri told ET. This rising demand comes despite continued warnings from healthcare professionals about the risks of indiscriminate painkiller use. Explosive growth The pain relief segment, particularly in urban markets, is largely driven by lifestyle factors such as gym injuries and sports-related strains. As a result, the combined market for analgesics and rubefacients has more than doubled, from Rs 6,820 crore in May 2020 to Rs 15,905 crore in May 2025, representing a compound annual growth rate (CAGR) of 18%. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Many Are Watching Tariffs - Few Are Watching What Nvidia Just Launched Seeking Alpha Read More Undo This is three times faster than the broader OTC market, which has grown at 6% CAGR to reach Rs 80,000 crore. Analgesics account for 75% of the pain management medication category. Paracetamol remains the dominant contributor, as per data from PharmaTrac, cited by ET. Sandeep Verma, who heads Bayer Pharmaceuticals' consumer health business for South Asia, noted a shift in perception since the Covid-19 outbreak. 'A lot of Indians view taking pain relief medication as a sign of weakness or worry about becoming dependent on it. Covid made many of us more aware of how stress, exhaustion, and even mild but recurring pain can chip away at our wellbeing and productivity,' he was quotde as saying. From chronic pain to lifestyle ailments Experts say that pain medications are being increasingly used to treat a wider range of issues, including inflammation and adjacent issues, leading to growing demand for pills. 'The analgesic segment that is dominated by paracetamols has been growing at a steady rate of 10%. This is because paracetamol medications are taken alongside other conditions that could include arthritis, any other bacterial or viral infection,' Sheetal Sapale, vice president, commercial, at PharmaTrac was quoted as saying. Nitin Kumar Sinha, consultant physician at WeCare Wellness in Mumbai, attributed the trend to rising lifestyle-related ailments. 'Lack of physical exercise, increase in body weight leading to knee and joint pain, anxiety, depression are all causes of increase in body pain, headaches or migraine,' he told ET. He also warned that self-medication is on the rise which can have serious consequences if used over a prolonged period of time, such as damage to the kidneys. IPCA's Zerodol SP, Janssen's Ultracet, GSK's Calpol, Micro Lab's Dolo, Torrent's Chymoral Forte and Cipla's Ibugesic Plus, are one of the top selling drugs. Most of these are prescription medications. Skin creams, allergies also see rise in OTC demand Pain relief isn't the only area where Indians are increasingly self-medicating. The demand for dermatological creams, traditionally prescribed by dermatologists, is also surging, particularly among Gen Z consumers. Bhanu Prakash, partner and healthcare services industry leader at Grant Thornton, said, 'Over-the-counter as a segment has grown post-Covid because of more knowledge and information for categories including anti-allergic medications, skin creams, tear drops among others.' Derma products, which are used to treat issues related to the skin and scalp, are now the second-largest non-prescription category after pain, expanding at a CAGR of 8% over the last five years, to become a Rs 14,854 crore market. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
16 hours ago
- Time of India
Ooh, Aah, Ouch? Billion-$ Market Feels Your Pain
Mumbai: Indians are increasingly popping over-the-counter pills, using sprays or rubbing in creams to soothe their aches and pains, adding more than a billion dollars to the pain management market over the past five years. The category is the biggest within the non-prescription segment, and has seen about five brands launched every week on average since the pandemic, industry executives said, citing Nielsen data. There were 1,552 brands -including Volini, Omnigel, Dolo and Saridon -to tackle the twinges in 2020; now, there are 2,771. Consumers are more attentive to alleviating any pain on a more immediate basis, said Shivam Puri, managing director at Cipla Health, which sells the biggest rubefacient brand, Omnigel. Rubefacient are gels and creams for topical application. "Rise of urbanisation and increase in chronic illnesses have led to the need for faster, more convenient formats that are accessible across platforms," said Puri. This is despite medical professionals advising caution on random use of painkillers. The pain relief category is often lifestyle-driven in urban markets, especially with gym and sports injuries. As a result, the market for analgesics (pain relief medication) and rubefacient more than doubled to Rs 15,905 crore as of May this year, from Rs 6,820 crore as of May 2020, growing at a compounded annual rate of 18%. This is three times faster than overall over-the-counter market growth, which rose at 6% CAGR to Rs 80,000 crore. Analgesics account for 75% of the pain medication market and within analgesics, paracetamol is the biggest contributor, according to data from market researcher PharmaTrac. Covid has changed Indians' views on pain management, said Sandeep Verma, head for consumer health business for South Asia at Bayer Pharmaceuticals, which sells Saridon. "A lot of Indians view taking pain relief medication as a sign of weakness or worry about becoming dependent on it. Covid made many of us more aware of how stress, exhaustion, and even mild but recurring pain can chip away at our wellbeing and productivity," he said. "More people are starting to understand that living with untreated pain impacts their quality of life." Experts said pain management medications are also used to treat inflammation and adjacent issues, widening the need for the pills. "The analgesic segment that is dominated by paracetamols has been growing at a steady rate of 10%. This is because paracetamol medications are taken alongside other conditions that could include arthritis, any other bacterial or viral infection," said Sheetal Sapale, vice president, commercial, at PharmaTrac. Nitin Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said lifestyle-related problems - including rising stress levels, lack of sleep and increasing obesity - are reasons for increasing demand for pain medications.
Economic Times
21 hours ago
- Economic Times
Sprays, pills, creams...ooh, aah, ouch? India's pain market is now a Rs 16,000 cr giant
Synopsis India's pain relief market has exploded post-pandemic, doubling to nearly ₹16,000 crore in just five years. From gels and sprays to pills like Dolo and Zerodol, pain meds are now a daily fix for everything from gym soreness to chronic stress. The shift is lifestyle-driven and increasingly normalised, but experts warn against unchecked self-medication. As the over-the-counter space booms, driven by awareness and ease of access, the line between relief and risk is getting worryingly thin. Agencies Mumbai: Indians are increasingly popping over-the-counter pills, using sprays or rubbing in creams to soothe their aches and pains, adding more than a billion dollars to the pain management market over the past five years. The category is the biggest within the non-prescription segment, and has seen about five brands launched every week on average since the pandemic, industry executives said, citing Nielsen data. There were 1,552 brands -including Volini, Omnigel, Dolo and Saridon -to tackle the twinges in 2020; now, there are 2,771. Consumers are more attentive to alleviating any pain on a more immediate basis, said Shivam Puri, managing director at Cipla Health, which sells the biggest rubefacient brand, Omnigel. Rubefacient are gels and creams for topical application. "Rise of urbanisation and increase in chronic illnesses have led to the need for faster, more convenient formats that are accessible across platforms," said Puri. This is despite medical professionals advising caution on random use of painkillers. The pain relief category is often lifestyle-driven in urban markets, especially with gym and sports injuries. As a result, the market for analgesics (pain relief medication) and rubefacient more than doubled to ₹15,905 crore as of May this year, from ₹6,820 crore as of May 2020, growing at a compounded annual rate of 18%. This is three times faster than overall over-the-counter market growth, which rose at 6% CAGR to ₹80,000 crore. Analgesics account for 75% of the pain medication market and within analgesics, paracetamol is the biggest contributor, according to data from market researcher PharmaTrac. Covid has changed Indians' views on pain management, said Sandeep Verma, head for consumer health business for South Asia at Bayer Pharmaceuticals, which sells Saridon. 'A lot of Indians view taking pain relief medication as a sign of weakness or worry about becoming dependent on it. Covid made many of us more aware of how stress, exhaustion, and even mild but recurring pain can chip away at our wellbeing and productivity,' he said.'More people are starting to understand that living with untreated pain impacts their quality of life."Experts said pain management medications are also used to treat inflammation and adjacent issues, widening the need for the pills.'The analgesic segment that is dominated by paracetamols has been growing at a steady rate of 10%. This is because paracetamol medications are taken alongside other conditions that could include arthritis, any other bacterial or viral infection,' said Sheetal Sapale, vice president, commercial, at Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said lifestyle-related problems — including rising stress levels, lack of sleep and increasing obesity — are reasons for increasing demand for pain medications.'Lack of physical exercise, increase in body weight leading to knee and joint pain, anxiety, depression are all causes of increase in body pain, headaches or migraine,' he said.'There is also an increase in people doing self-medication and several mandatory prescription drugs, strong painkillers and anti-inflammatory medications — that can have severe harmful effects, such as damage to the kidneys, if used over a prolonged period — are today available easily at chemist shops without prescriptions,' said top-selling drugs in the pain category are IPCA's Zerodol SP, Janssen's Ultracet, GSK's Calpol, Micro Lab's Dolo, Torrent's Chymoral Forte and Cipla's Ibugesic Plus. A majority of them are prescription pain is not the only category that people are self-medicating in since the pandemic. Skin creams, earlier prescribed by dermatologists, are drawing a consumer base, especially Gen Z products, which treat scalp and skin issues and form the second biggest category after pain, expanded 8% CAGR over the past five years and are now a ₹14,854 crore Prakash, partner and healthcare services industry leader at Grant Thornton, said, 'Over-the-counter as a segment has grown post-Covid because of more knowledge and information for categories including anti-allergic medications, skin creams, tear drops among others.'
